Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

A groundbreaking approach slows tumor growth while boosting the immune system’s defense against cancer cells. Prostate cancer ranks as the second most common cancer among men globally. Despite recent ...

After a comprehensive two-year follow-up, researchers at the UCLA Health Jonsson Comprehensive Cancer Center found that ...

Overtreatment of prostate cancer is increasing in the United States among men with limited life expectancy, a new s ...

Photodynamic therapy is an accepted but underappreciated treatment for solid cancers Invion has announced promising results from its first-in-human trial, for prostate cancer The company ... drugs ...

Many other health problems can also cause ... of cancer treatments and prostate cancer surgery choices from the National Cancer Institute. Anything that increases your chance of getting a disease is ...

“Metastatic prostate cancer is the second most common cause of cancer-related death in men. Having a novel combination of well-tolerated medications significantly improving overall survival rates is ...

Keytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In India, its high cost limits access. With patents expiring soon, ...

Prostate cancer is Australia’s most commonly diagnosed cancer. One in six men will be diagnosed by the time they turn 85. Cancers are abnormal groups of cells that grow uncontrollably and start ...

Prostate cancer ... So how does it work? And how does it compare to existing therapies? Stereotactic radiotherapy uses high doses of radiation to target and kill cancer cells.

The second approval is for KEYTRUDA combined with chemoradiotherapy (CRT) for adults with FIGO 2014 Stage III-IVA locally advanced cervical cancer who have not undergone prior definitive therapy. With ...